Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
Shohei Yamamoto, Ami Fukunaga, Akihito Tanaka, Junko S. Takeuchi, Yosuke Inoue, Moto Kimura, Kenji Maeda, Gohzoh Ueda, Tetsuya Mizoue, Mugen Ujiie, Wataru Sugiura, Norio Ohmagari
Topics & Concepts
ReactogenicityCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineVirology2019-20 coronavirus outbreakCoronavirusBetacoronavirusAntibodySpike ProteinTiterImmune systemSevere acute respiratory syndrome coronavirusImmunologyDiseaseImmunogenicityVirusOutbreakInfectious disease (medical specialty)Internal medicineSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies